These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27896908)

  • 1. Bixalomer in Hyperphosphatemic Patients With Chronic Kidney Disease Not on Dialysis: Phase 3 Randomized Trial.
    Akizawa T; Origasa H; Kameoka C; Tsukada J; Kuroishi K; Yamaguchi Y
    Ther Apher Dial; 2016 Dec; 20(6):588-597. PubMed ID: 27896908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Safety and Efficacy of Bixalomer in Hyperphosphatemic Patients With Chronic Kidney Disease Not on Dialysis.
    Akizawa T; Tsukada J; Kameoka C; Kuroishi K; Yamaguchi Y
    Ther Apher Dial; 2017 Apr; 21(2):173-179. PubMed ID: 28194884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-finding study of bixalomer in patients with chronic kidney disease on hemodialysis with hyperphosphatemia: a double-blind, randomized, placebo-controlled and sevelamer hydrochloride-controlled open-label, parallel group study.
    Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kanoh H
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():24-32. PubMed ID: 24975892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia.
    Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kawasaki S;
    Ther Apher Dial; 2014 Apr; 18(2):122-31. PubMed ID: 24720402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment of hyperphosphatemia with bixalomer in Japanese hemodialysis patients.
    Akizawa T; Kameoka C; Kaneko Y; Kawasaki S;
    Ther Apher Dial; 2013 Dec; 17(6):612-9. PubMed ID: 24330556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experiences of bixalomer usage at our hospital.
    Shima H; Makino R; Hata K; Ban A; Funao K; Sugita S; Furumitsu Y; Inoue K; Yoshimoto M; Okamura M
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():13-8. PubMed ID: 24975890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical effects of the new phosphorus binder, bixalomer in hemodialysis patients switched from sevelamer hydrochloride.
    Gen S; Sasaki T; Saito K; Nobe K; Nodaira Y; Ikeda N
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():8-12. PubMed ID: 24975889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Effects of Add-On Tenapanor for Hemodialysis Patients with Refractory Hyperphosphatemia.
    Shigematsu T; Une Y; Ikejiri K; Kanda H; Fukagawa M; Akizawa T
    Am J Nephrol; 2021; 52(6):496-506. PubMed ID: 34098559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study.
    Koiwa F; Terao A
    Clin Exp Nephrol; 2017 Jun; 21(3):513-522. PubMed ID: 27389681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bixalomer, a novel phosphate binder with a small swelling index, improves hyperphosphatemia in chronic kidney disease rat.
    Taniguchi K; Kakuta H
    Eur J Pharmacol; 2015 Nov; 766():129-34. PubMed ID: 26452517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of switching from sevelamer hydrochloride to bixalomer on laboratory parameters in hemodialysis patients.
    Furukawa K; Ikawa T; Yokoi S; Yokouchi S; Kato K; Ueno M; Takahashi J
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():2-7. PubMed ID: 24975888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease.
    Fathallah-Shaykh S; Drozdz D; Flynn J; Jenkins R; Wesseling-Perry K; Swartz SJ; Wong C; Accomando B; Cox GF; Warady BA
    Pediatr Nephrol; 2018 Feb; 33(2):325-333. PubMed ID: 28900759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial.
    Takahara Y; Matsuda Y; Takahashi S; Shigematsu T;
    Clin Nephrol; 2014 Sep; 82(3):181-90. PubMed ID: 25079863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, Double-Blind, Placebo-Controlled, Withdrawal Study of Colestilan after Dose Titration in Chronic Kidney Disease Dialysis Patients with Hyperphosphatemia.
    Hertel J; Locatelli F; Spasovski G; Dimkovic N; Wanner C
    Nephron; 2015; 130(4):229-38. PubMed ID: 26184491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of hyperphosphatemia with bixalomer in Japanese patients on long-term hemodialysis with gastrointestinal symptoms.
    Ito K; Takeshima A; Shishido K; Wakasa M; Kumata C; Matsuzaka K; Nakajima Y; Ogata H
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():19-23. PubMed ID: 24975891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY).
    Pergola PE; Rosenbaum DP; Yang Y; Chertow GM
    J Am Soc Nephrol; 2021 Jun; 32(6):1465-1473. PubMed ID: 33766811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary management of phosphorus retention in chronic kidney disease: a review.
    Amiri FS
    Clin Exp Nephrol; 2015 Dec; 19(6):985-99. PubMed ID: 26032778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.
    Yokoyama K; Hirakata H; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Block GA
    Clin J Am Soc Nephrol; 2014 Mar; 9(3):543-52. PubMed ID: 24408120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study.
    Locatelli F; Spasovski G; Dimkovic N; Wanner C; Dellanna F; Pontoriero G
    Nephrol Dial Transplant; 2014 May; 29(5):1061-73. PubMed ID: 24302608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.